NLRP6 and colitis: A potential mechanism was provided by the finding that NLRP6 acts as a negative regulator of NF-κB and MAPK activation, and reduces the levels of cytokines and chemokines during infections with intestinal pathogens or epithelial barrier breach as observed during experimental models of colitis (38).